While previous similar approaches demonstrated EV miRNA detection in CD63‐positive EVs[24] or all EVs,[29] in our pilot study, we showed that quantification of miRNA‐positive EV counts in the tumor‐derived EV subpopulation could further increase the difference in plasma EV analysis between cancer and healthy control groups. The gene discussed is CD63; the disease is cancer.